<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140569</url>
  </required_header>
  <id_info>
    <org_study_id>Gelf-94</org_study_id>
    <nct_id>NCT00140569</nct_id>
  </id_info>
  <brief_title>Randomized Study for Patients With Follicular Lymphoma Needing Treatment</brief_title>
  <official_title>Randomized Study for Patients With Follicular Lymphoma Needing Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      2 parallel studies.

        -  For young patients (18-60 years): randomization between CHVP + interferon for 18 months
           and 4 CHOP followed by autotransplant after TBI

        -  For elderly patients (&gt;60 years): randomization between CHVP + interferon for 18 months
           and fludarabine 5 days every months for 6 months
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 parallel studies.

        -  For young patients (18-60 years): randomization between CHVP + interferon for 18 months
           and 4 CHOP followed by autotransplant after TBI

        -  For elderly patients (&gt;60 years): randomization between CHVP + interferon for 18 months
           and fludarabine 5 days every months for 6 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1994</start_date>
  <completion_date>January 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Follicular Lymphoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CHVP + interferon</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CHOP + TBI and autotransplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  study 1 (young patients): being less than 61 years old with a follicular lymphoma and
             needing to be treated because of high LDH level, high beta-2 microglobulin level, poor
             performance status, or large tumoral mass (lymph node &gt;7 cm, symptomatic splenomegaly,
             pleura effusion, or sign of compression by the tumor mass)

          -  study 2 (elderly patients): being older than 60 years with a follicular lymphoma and
             needing to be treated because of high LDH level, high beta-2 microglobulin level, poor
             performance status, or large tumoral mass (lymph node &gt;7 cm, symptomatic splenomegaly,
             pleura effusion, or sign of compression by the tumor mass)

        Exclusion Criteria:

          -  contra-indication to anthracycline or interferon

          -  transformation into large cell lymphoma

          -  previous treatment

          -  localized stage without criteria of large tumor mass

          -  patients HIV+
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Coiffier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Sebban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'atude des lymphome de l'adulte</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <results_reference>
    <citation>Coiffier B, Neidhardt-Bérard EM, Tilly H, Belanger C, Bouabdallah R, Haioun C, Brice P, Péaud PY, Pico JL, Janvier M, Solal-Celigny P, Brousse N. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 1999 Oct;10(10):1191-7.</citation>
    <PMID>10586336</PMID>
  </results_reference>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>August 31, 2005</last_update_submitted>
  <last_update_submitted_qc>August 31, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2005</last_update_posted>
  <keyword>follicular lymphoma</keyword>
  <keyword>CHVP + interferon</keyword>
  <keyword>fludarabine</keyword>
  <keyword>autotransplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

